425: Alumis to Acquire ACELYRIN in All-Stock Merger, Creating Late-Stage Clinical Biopharma with Extended Cash Runway

Alumis Inc. and ACELYRIN, Inc. have announced a definitive agreement for an all-stock merger, aiming to create a well-capitalized biopharmaceutical company focused on immune-mediated diseases with a cash runway into 2027.

Summary

• Alumis Inc. and ACELYRIN, Inc. have entered into a merger agreement where Alumis will acquire ACELYRIN in an all-stock transaction.
• ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock.
• Post-merger, Alumis stockholders are expected to own approximately 52% and ACELYRIN stockholders approximately 48% of the combined company.
• The combined company will operate under the name Alumis and will be led by the current Alumis executive team.
• The merger is expected to close in the second quarter of 2025, pending stockholder approval and customary closing conditions.
• The pro forma cash position of the combined company is estimated at ~$737 million as of December 31, 2024, providing a cash runway into 2027.
• The combined company will focus on developing and commercializing transformative therapies for immune-mediated diseases.
• Key pipeline assets include ESK-001 (TYK2 inhibitor) for psoriasis and SLE, A-005 (CNS-penetrant TYK2 inhibitor) for MS, and lonigutamab (anti-IGF-1R) for thyroid eye disease (TED).
• Alumis plans to invest approximately $25-50 million to evaluate lonigutamab's potential in TED following the merger.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the merger, highlighting the potential benefits and synergies. However, it also acknowledges the risks and uncertainties associated with the transaction and drug development, preventing a higher score.

Positives

• The merger creates a well-capitalized company with a strong cash position of ~$737 million, providing runway into 2027.
• The combined company has a diverse pipeline of clinical programs targeting immune-mediated diseases.
• Alumis' ESK-001 has shown promising results in psoriasis trials, with Phase 3 topline data expected in 1Q 2026.
• Alumis' A-005 is a potentially first-in-class CNS-penetrant TYK2 inhibitor with opportunities in neuroinflammatory diseases.
• The addition of ACELYRIN's lonigutamab provides an opportunity to expand into thyroid eye disease (TED).
• The Kaken collaboration provides non-dilutive capital and validates the commercial potential of ESK-001.
• The LUMUS trial in SLE incorporates learnings from past trials to mitigate challenges and increase the probability of success.

Negatives

• The merger is subject to stockholder approval and customary closing conditions, which could delay or prevent the transaction.
• The success of the combined company depends on the successful development and commercialization of its product candidates, which is subject to various risks and uncertainties.
• The integration of ACELYRIN's operations and personnel may present challenges.
• The value of Alumis securities to be issued in the transaction is subject to market fluctuations.
• Clinical trial results are not guaranteed, and topline data may not be positive.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Required approvals for the transaction may not be received.
• The announcement of the transaction may affect Alumis' and ACELYRIN's ability to retain key personnel and maintain relationships.
• The transaction may divert management's attention from ongoing business operations.
• Legal proceedings related to the transaction could arise.
• Economic, business, and competitive factors may adversely affect Alumis or ACELYRIN.
• The anticipated benefits and synergies of the transaction may not be fully realized.
• Legislative, regulatory, economic, competitive, and technological changes could impact the company.
• Integration of the transaction post-closing may not occur as anticipated.
• Delays in initiating, enrolling, or completing preclinical studies and clinical trials could occur.

Future Outlook

The combined company aims to advance its pipeline of clinical programs, with multiple data readouts expected in the near term and a focus on developing transformative therapies for immune-mediated diseases. The company expects to finalize a clinical development plan for lonigutamab following the closing of the merger.

Management Comments

• Post transaction close, we expect to evaluate lonigutamabs promising potential differentiation profile in TED with approximately $25 50M of committed capital and the combined expertise of Alumis and the lonigutamab team.

Industry Context

The merger reflects a trend in the biopharmaceutical industry towards consolidation to create companies with stronger financial positions and more diversified pipelines. The focus on immune-mediated diseases aligns with the growing market for therapies targeting these conditions.

Comparison to Industry Standards

• ESK-001's Phase 2 OLE data shows PASI 75 response rates in the high biologics range, suggesting it could be competitive with established treatments like Skyrizi, Cosentyx, and Stelara.
• The development of A-005 as a CNS-penetrant TYK2 inhibitor positions it to potentially compete in the multiple sclerosis market, which is dominated by drugs like Ocrevus and Tysabri.
• Lonigutamab's potential as a best-in-class anti-IGF-1R therapy in TED could make it a competitor to Tepezza, the current market leader.

Stakeholder Impact

• Shareholders of both Alumis and ACELYRIN will be impacted by the merger, with changes in ownership and potential value of their holdings.
• Employees of both companies may experience changes in roles and responsibilities as a result of the integration.
• Patients may benefit from the development of new therapies for immune-mediated diseases.
• The combined company's suppliers and partners may see changes in their relationships.

Next Steps

• Obtain approval from Alumis and ACELYRIN stockholders.
• Satisfy other customary closing conditions.
• Close the merger, expected in the second quarter of 2025.
• Finalize the clinical development plan for lonigutamab.
• Initiate Phase 2 study in MS patients with A-005 in 2H25.
• Readout of Phase 3 topline data for ESK-001 in psoriasis expected in 1Q 2026.
• Readout of Phase 2b topline data for ESK-001 in SLE expected in 2026.
• Readout of Phase 2 topline data for A-005 in MS expected in 2026.

Key Dates

Keywords

merger, Alumis, ACELYRIN, TYK2 inhibitor, ESK-001, A-005, lonigutamab, psoriasis, systemic lupus erythematosus, multiple sclerosis, thyroid eye disease, clinical trials, biopharmaceutical, immune-mediated diseases